{"id":"https://openalex.org/W2912374321","doi":"https://doi.org/10.1007/s11864-019-0607-8","title":"Targeted Therapy and Immunotherapy for Melanoma in Japan","display_name":"Targeted Therapy and Immunotherapy for Melanoma in Japan","alternate_titles":[],"publication_year":2019,"publication_date":"2019-01-01","ids":{"openalex":"https://openalex.org/W2912374321","doi":"https://doi.org/10.1007/s11864-019-0607-8","mag":"2912374321","pmid":"https://pubmed.ncbi.nlm.nih.gov/30675668","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6344396"},"language":"en","primary_location":{"id":"doi:10.1007/s11864-019-0607-8","doi":"https://doi.org/10.1007/s11864-019-0607-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11864-019-0607-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11864-019-0607-8.pdf","source":{"id":"https://openalex.org/S208090617","display_name":"Current Treatment Options in Oncology","issn_l":"1534-6277","issn":["1534-6277","1527-2729"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Treatment Options in Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2912374321"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s11864-019-0607-8.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047984722","display_name":"Kenjiro Namikawa","orcid":"https://orcid.org/0000-0003-2763-7346","observed_orcids":["https://orcid.org/0000-0003-2763-7346"]},"institutions":[{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kenjiro Namikawa","raw_affiliation_strings":["Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. knamikaw@ncc.go.jp","Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. knamikaw@ncc.go.jp","institution_ids":["https://openalex.org/I4405285273"]},{"raw_affiliation_string":"Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan","institution_ids":["https://openalex.org/I4405285273"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001893646","display_name":"Naoya Yamazaki","orcid":"https://orcid.org/0000-0002-9638-0428","observed_orcids":["https://orcid.org/0000-0002-9638-0428"]},"institutions":[{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Naoya Yamazaki","raw_affiliation_strings":["Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan","institution_ids":["https://openalex.org/I4405285273"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5047984722"],"corresponding_institution_ids":["https://openalex.org/I4405285273"],"apc_list":{"value":3760,"currency":"USD","value_usd":3760},"apc_paid":{"value":3760,"currency":"USD","value_usd":3760},"fwci":0.9637,"has_fulltext":true,"cited_by_count":171,"citation_normalized_percentile":{"value":0.70900874,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"20","issue":"1","first_page":"7","last_page":"7"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.8295999765396118,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.8295999765396118,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.10530000180006027,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.05959999933838844,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9539999961853027},{"id":"https://openalex.org/keywords/acral-melanoma","display_name":"acral melanoma","score":0.9190000295639038},{"id":"https://openalex.org/keywords/mucosal-melanoma","display_name":"mucosal melanoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7509999871253967},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.7620000243186951},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9580000042915344},{"id":"https://openalex.org/keywords/kit-mutations","display_name":"KIT mutations","score":0.7179999947547913},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.7749999761581421},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.859000027179718},{"id":"https://openalex.org/keywords/oncolytic-viruses","display_name":"oncolytic viruses","score":0.7419999837875366},{"id":"https://openalex.org/keywords/talimogene-laherparepvec","display_name":"talimogene laherparepvec","score":0.8920000195503235},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.921999990940094},{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.7860000133514404},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.5839999914169312},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9570000171661377},{"id":"https://openalex.org/keywords/access-to-innovative-medicines","display_name":"access to innovative medicines","score":0.47699999809265137},{"id":"https://openalex.org/keywords/japan","display_name":"Japan","score":0.609000027179718}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8977638483047485},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8501601815223694},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.8421909809112549},{"id":"https://openalex.org/C21790070","wikidata":"https://www.wikidata.org/wiki/Q18030215","display_name":"Neuroblastoma RAS viral oncogene homolog","level":5,"score":0.697125256061554},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.66450035572052},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.5311744809150696},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5152192711830139},{"id":"https://openalex.org/C2781186586","wikidata":"https://www.wikidata.org/wiki/Q6931266","display_name":"Mucosal melanoma","level":3,"score":0.48144692182540894},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4587249457836151},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.4538787603378296},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4416589140892029},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4276915192604065},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.42595452070236206},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.36848002672195435},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3224157691001892},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3159204125404358},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.11234855651855469},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.0},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1007/s11864-019-0607-8","doi":"https://doi.org/10.1007/s11864-019-0607-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11864-019-0607-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11864-019-0607-8.pdf","source":{"id":"https://openalex.org/S208090617","display_name":"Current Treatment Options in Oncology","issn_l":"1534-6277","issn":["1534-6277","1527-2729"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Treatment Options in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5356241","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6344396","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6344396","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6344396/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Curr Treat Options Oncol","raw_type":"Text"},{"id":"pmid:30675668","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30675668","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current treatment options in oncology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s11864-019-0607-8","doi":"https://doi.org/10.1007/s11864-019-0607-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11864-019-0607-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11864-019-0607-8.pdf","source":{"id":"https://openalex.org/S208090617","display_name":"Current Treatment Options in Oncology","issn_l":"1534-6277","issn":["1534-6277","1527-2729"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Treatment Options in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3382579972","display_name":null,"funder_award_id":"29-A-3","funder_id":"https://openalex.org/F4320311405","funder_display_name":"Japan Agency for Medical Research and Development"}],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"},{"id":"https://openalex.org/F4320311405","display_name":"Japan Agency for Medical Research and Development","ror":"https://ror.org/004rtk039"},{"id":"https://openalex.org/F4320311653","display_name":"Taiho Pharmaceutical","ror":"https://ror.org/02v50dx14"},{"id":"https://openalex.org/F4320317814","display_name":"Sysmex Corporation","ror":"https://ror.org/00gfstq19"},{"id":"https://openalex.org/F4320318399","display_name":"Kaken Pharmaceutical","ror":"https://ror.org/0059xpe44"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320322359","display_name":"Kyowa Hakko Kirin","ror":"https://ror.org/0586k5242"},{"id":"https://openalex.org/F4320324230","display_name":"Toray Industries","ror":"https://ror.org/029xh1r47"},{"id":"https://openalex.org/F4320326474","display_name":"Teijin Pharma","ror":"https://ror.org/001144c36"},{"id":"https://openalex.org/F4320327845","display_name":"Ono Pharmaceutical","ror":"https://ror.org/022jefx64"},{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2912374321.pdf","grobid_xml":"https://content.openalex.org/works/W2912374321.grobid-xml"},"referenced_works_count":84,"referenced_works":["https://openalex.org/W1147117258","https://openalex.org/W1585375233","https://openalex.org/W1828940258","https://openalex.org/W1950829641","https://openalex.org/W1963976650","https://openalex.org/W1965370740","https://openalex.org/W1989121777","https://openalex.org/W2015682571","https://openalex.org/W2017095180","https://openalex.org/W2019496774","https://openalex.org/W2027891368","https://openalex.org/W2034248634","https://openalex.org/W2070825440","https://openalex.org/W2079641245","https://openalex.org/W2096223992","https://openalex.org/W2096387850","https://openalex.org/W2097691839","https://openalex.org/W2097995306","https://openalex.org/W2099289479","https://openalex.org/W2103152130","https://openalex.org/W2109274792","https://openalex.org/W2111404068","https://openalex.org/W2112121482","https://openalex.org/W2112403746","https://openalex.org/W2119787454","https://openalex.org/W2121545342","https://openalex.org/W2123363005","https://openalex.org/W2128035403","https://openalex.org/W2128542677","https://openalex.org/W2130723808","https://openalex.org/W2136474966","https://openalex.org/W2143923888","https://openalex.org/W2147474070","https://openalex.org/W2152897456","https://openalex.org/W2156266404","https://openalex.org/W2160766792","https://openalex.org/W2164130643","https://openalex.org/W2166262263","https://openalex.org/W2320786076","https://openalex.org/W2336695065","https://openalex.org/W2342956596","https://openalex.org/W2412250098","https://openalex.org/W2473956396","https://openalex.org/W2491982852","https://openalex.org/W2515516401","https://openalex.org/W2519469881","https://openalex.org/W2529373149","https://openalex.org/W2553340100","https://openalex.org/W2557238488","https://openalex.org/W2560367415","https://openalex.org/W2572174216","https://openalex.org/W2592369722","https://openalex.org/W2594274861","https://openalex.org/W2594529508","https://openalex.org/W2600124489","https://openalex.org/W2611187032","https://openalex.org/W2611270905","https://openalex.org/W2614056985","https://openalex.org/W2650204451","https://openalex.org/W2733884328","https://openalex.org/W2736167445","https://openalex.org/W2747107882","https://openalex.org/W2748716584","https://openalex.org/W2752210999","https://openalex.org/W2752227448","https://openalex.org/W2753432434","https://openalex.org/W2753466295","https://openalex.org/W2762638624","https://openalex.org/W2770760027","https://openalex.org/W2788938550","https://openalex.org/W2791686077","https://openalex.org/W2793817570","https://openalex.org/W2797309423","https://openalex.org/W2801342700","https://openalex.org/W2806357747","https://openalex.org/W2810292296","https://openalex.org/W2890146531","https://openalex.org/W2890383583","https://openalex.org/W2891205725","https://openalex.org/W2896253897","https://openalex.org/W2896600825","https://openalex.org/W2899505264","https://openalex.org/W2901290714","https://openalex.org/W2946205311"],"related_works":["https://openalex.org/W4389685216","https://openalex.org/W2094848657","https://openalex.org/W2793923116","https://openalex.org/W35498444","https://openalex.org/W2898586375","https://openalex.org/W2208209700","https://openalex.org/W4410991311","https://openalex.org/W3171006409","https://openalex.org/W4404540473","https://openalex.org/W4409215802"],"abstract_inverted_index":{"OPINION":[0],"STATEMENT:":[1],"Melanoma":[2],"has":[3],"several":[4,101],"clinically":[5],"and":[6,21,63,85,99,141,195,219,233,254,276,284,378,403],"pathologically":[7],"distinguishable":[8],"subtypes,":[9,20],"which":[10,88,324],"also":[11,250],"differ":[12],"genetically.":[13],"Mutation":[14],"patterns":[15],"vary":[16],"among":[17],"different":[18],"melanoma":[19,70,74,160,415],"efficacy":[22,405],"of":[23,31,35,39,66,113,125,139,146,149,178,217,243,292,307,332,357,393,406,414],"immune-checkpoint":[24],"inhibitors":[25,143,170,186],"differs":[26],"depending":[27],"on":[28,369,385],"the":[29,36,61,105,114,147,267,293,330,333,344,349,354,361,386,391,398,420],"subtype":[30],"melanoma.":[32,136,156,302],"In":[33,157,266,375],"spite":[34],"recent":[37,355],"revolution":[38],"systemic":[40,67],"therapies":[41,68],"for":[42,69,151,390,411],"advanced":[43,154],"melanoma,":[44,127,228,237],"access":[45,78],"to":[46,59,79,189,348,367],"innovative":[47,80],"agents":[48,81],"is":[49,75,82,120,144,203,317,326],"still":[50],"restricted":[51],"in":[52,71,91,96,110,122,134,164,183,207,223,262,281,287,319,323,400,419],"many":[53],"countries.":[54],"This":[55],"review":[56,261],"article":[57],"aimed":[58],"describe":[60],"epidemiology":[62],"current":[64],"status":[65],"Japan,":[72,288],"where":[73],"rare,":[76],"but":[77,128],"available.":[83],"Acral":[84],"mucosal":[86,135,196,236,301,379],"melanomas,":[87],"are":[89,131,187,258],"common":[90],"Asian":[92],"populations,":[93],"predominantly":[94],"occur":[95],"sun-protected":[97],"areas":[98],"share":[100],"biological":[102],"features.":[103],"Both":[104],"melanomas":[106,197,380],"harbor":[107],"KIT":[108,162,169],"mutation":[109,119,163,201],"approximately":[111,123],"15%":[112],"cases;":[115],"BRAF":[116,140],"or":[117,167],"NRAS":[118],"found":[121],"10-15%":[124],"acral":[126,194,232,377],"these":[129,358,412],"mutations":[130],"less":[132,191],"frequent":[133],"Combined":[137],"use":[138],"MEK":[142],"one":[145],"standards":[148],"care":[150],"patients":[152,158,226,299,370],"with":[153,159,227,231,235,300,310,371],"BRAF-mutant":[155],"harboring":[161],"exon":[165],"11":[166],"13,":[168],"can":[171],"be":[172,190,341,365,417],"a":[173],"treatment":[174,392],"option;":[175],"however,":[176],"none":[177],"them":[179],"have":[180,381],"been":[181,382],"approved":[182,280],"Japan.":[184],"Immune-checkpoint":[185],"expected":[188],"effective":[192],"against":[193],"because":[198],"their":[199],"somatic":[200],"burden":[202],"lower":[204],"than":[205],"those":[206],"non-acral":[208,394],"cutaneous":[209,395],"melanomas.":[210,396],"A":[211,303],"recently":[212],"completed":[213],"phase":[214,264,295,304],"II":[215,373],"trial":[216,306,363],"nivolumab":[218,274],"ipilimumab":[220],"combination":[221],"therapy":[222,309],"30":[224],"Japanese":[225],"including":[229],"seven":[230],"12":[234],"demonstrated":[238],"an":[239],"objective":[240],"response":[241],"rate":[242],"43%.":[244],"Regarding":[245],"oncolytic":[246],"viruses,":[247],"canerpaturev":[248],"(C-REV,":[249],"known":[251],"as":[252],"HF10)":[253],"talimogene":[255],"laherparepvec":[256],"(T-VEC)":[257],"currently":[259],"under":[260],"early":[263],"trials.":[265],"adjuvant":[268,294,308],"setting,":[269],"dabrafenib":[270],"plus":[271],"trametinb":[272],"combination,":[273],"monotherapy,":[275],"pembrolizumab":[277],"monotherapy":[278],"were":[279],"July,":[282],"August,":[283],"December":[285],"2018":[286],"respectively.":[289],"However,":[290],"most":[291],"III":[296,305],"trials":[297],"excluded":[298],"locoregional":[311],"interferon":[312],"(IFN)-\u03b2":[313],"versus":[314],"surgery":[315],"alone":[316],"ongoing":[318],"Japan":[320],"(JCOG1309,":[321],"J-FERON),":[322],"IFN-\u03b2":[325],"injected":[327],"directly":[328],"into":[329],"site":[331],"primary":[334],"tumor":[335],"postoperatively,":[336],"so":[337],"that":[338],"it":[339],"would":[340],"drained":[342],"through":[343],"untreated":[345],"lymphatic":[346],"route":[347],"regional":[350],"node":[351],"basin.":[352],"After":[353],"approval":[356],"new":[359],"agents,":[360],"JCOG1309":[362],"will":[364],"revised":[366],"focus":[368],"stage":[372],"disease.":[374],"conclusion,":[376],"treated":[383],"based":[384],"available":[387],"medical":[388],"evidence":[389],"Considering":[397],"differences":[399],"genetic":[401],"backgrounds":[402],"therapeutic":[404,409],"immunotherapy,":[407],"specialized":[408],"strategies":[410],"subtypes":[413],"should":[416],"established":[418],"future.":[421]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2912374321","counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":29},{"year":2024,"cited_by_count":28},{"year":2023,"cited_by_count":54},{"year":2022,"cited_by_count":25},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2019-02-21T00:00:00"}
